Last reviewed · How we verify

Placebo matched with pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Phase 3 active Small molecule

Placebo matched with pregabalin is a Gabapentinoid Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. It is currently in Phase 3 development for Neuropathic pain, Partial-onset seizures, Generalized anxiety disorder.

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain, Partial-onset seizures, Generalized anxiety disorder.

At a glance

Generic namePlacebo matched with pregabalin
SponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug classGabapentinoid
TargetAlpha-2-delta-1 subunit of voltage-gated calcium channels
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

Pregabalin is a gabapentinoid that decreases calcium influx into nerve terminals by binding to the alpha-2-delta-1 subunit of presynaptic voltage-gated calcium channels. This reduces the release of glutamate, noradrenaline, and substance P, thereby dampening neuronal excitability. The mechanism underlies its efficacy in neuropathic pain, seizures, and anxiety disorders.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo matched with pregabalin

What is Placebo matched with pregabalin?

Placebo matched with pregabalin is a Gabapentinoid drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., indicated for Neuropathic pain, Partial-onset seizures, Generalized anxiety disorder.

How does Placebo matched with pregabalin work?

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.

What is Placebo matched with pregabalin used for?

Placebo matched with pregabalin is indicated for Neuropathic pain, Partial-onset seizures, Generalized anxiety disorder, Postherpetic neuralgia.

Who makes Placebo matched with pregabalin?

Placebo matched with pregabalin is developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (see full Pfizer's Upjohn has merged with Mylan to form Viatris Inc. pipeline at /company/pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc).

What drug class is Placebo matched with pregabalin in?

Placebo matched with pregabalin belongs to the Gabapentinoid class. See all Gabapentinoid drugs at /class/gabapentinoid.

What development phase is Placebo matched with pregabalin in?

Placebo matched with pregabalin is in Phase 3.

What are the side effects of Placebo matched with pregabalin?

Common side effects of Placebo matched with pregabalin include Dizziness, Somnolence, Peripheral edema, Weight gain, Blurred vision, Ataxia.

What does Placebo matched with pregabalin target?

Placebo matched with pregabalin targets Alpha-2-delta-1 subunit of voltage-gated calcium channels and is a Gabapentinoid.

Related